DoseMe Announces 2023 Highlights; Precision Dosing Fast-Tracking to Top Trend in 2024
DoseMe, a leading provider of precision dosing software for Model Informed Precision Dosing (MIPD) and creators of DoseMeRx and DoseMe Analytics, today announces its company highlights for 2023 and outlook for 2024.
"In the post-COVID landscape, health systems are coping with stretched resources while striving to maintain high-quality patient care. Recognizing these challenges, an increasing number of institutions are adopting DoseMe analytics and using their data in a meaningful way to impact patient care," said Paul Edwards, CEO at DoseMe. "This growing trend underpins the need for therapeutic drug monitoring and we believe the company is poised for breakthrough growth in 2024."
Only dosing platform that is HITRUST Risk-based certified, renewed 2-year certification demonstrating the highest level of information protection assurance
Science and Product
Clinical Advisory Board Leadership - appointment of Dr. Marc Scheetz to chair, bringing a wealth of experience and background in pharmacometrics with commitment to dose optimization.
Redefining medication efficacy standards ? addition of predictive models to extend beyond traditional antibiotics, initiating a fundamental change in dosing practices, empowering clinicians to improve patient outcomes through precision medicine.
Partners and Customers
Expanded distribution network with exclusive resellers across 29 countries.
Broaden genetic biomarker capabilities for precision dosing, enabling the capability in multiple hospitals resulting in significant improvements.
In a series of strategic implementations, DoseMe has partnered with several distinguished healthcare institutions looking to optimize their therapeutic protocols.
Advanced compliance with dosing protocols, significantly diminishing adverse events such as toxicity and acute kidney injuries (AKI) and enhancing the overall level of patient care.
Integrated advanced dosing algorithms and genetic biomarker analysis into their patient care protocols, enabling more personalized treatments aligned with individual patient profiles and genetic markers.
Pharma Manufacturing Editorial Board Honors DoseMe Analytics as Top Technology.
Coverage in Bio-IT World, Express Healthcare Management, Hospital Management, Pharma Manufacturing, PharmaVoice and Technology Networks.
Global Education and Application - webinar tailored for Australian healthcare practitioners titled "From Theory to Practice: Maximizing Aminoglycoside Efficacy with the AUC-guided TDM." This educational endeavor demonstrates our commitment to supporting healthcare systems worldwide in adopting precision dosing strategies that optimize therapy outcomes.
The FDA recommendation in early 2023 to use AUC is an important and significant shift in vancomycin dosing and monitoring augmenting the mission to advance better patient outcomes. Research reports continue to include precision medicine, and dosing specifically, as a key trend in 2024 and beyond.
Among the operational plans for 2024, DoseMe will continue to build new drug models to broaden the MIPD platform, diversify the channels and add new partners that will enable the company to offer a wide range of AI-powered systems for real-time patient care. For more information, reach out to https://doseme-rx.com/contact.
DoseMe combines smart technology with science, leveraging clinically-validated PK/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize a dose in seconds. The platform is HIPAA, ISO & FDA compliant and the only Bayesian dosing platform to be HITRUST CSF certified. For more information on successful applications of its products, DoseMeRx and DoseMe Analytics, visit https://doseme-rx.com/success-stories.
TDCX Inc. ("TDCX" or the "Company") , an award-winning digital customer experience (CX) solutions provider for technology and blue-chip companies, today announced the filing of its annual report on Form 20-F for the fiscal year ended December 31,...
Security and threat intelligence technology company, Silobreaker today announced the addition of automatic collection, AI-enhanced analysis, and alerting on 8-K cybersecurity incident filings made to the US Securities and Exchange Commission (SEC)....
Revvity, Inc. , today reported financial results for the first quarter ended March 31, 2024.
The Company reported GAAP earnings per share of $0.21, as compared to $4.50 in the same period a year ago. GAAP revenue for the quarter was $650 million,...
Vena, the Complete Planning platform loved by finance and trusted by business, today announced that tickets for Excelerate Finance 2024, the premier annual conference for finance, operations and business leaders, have sold out. The event will be held...
TOPseven, a leading developer of renewable energy technology, is launching its latest innovation, the TOP7 LPS 2.0, at CleanPower 2024. Situated at booth number 3220, TOPseven will showcase a state-of-the-art product designed to transform Lightning...
Huasun Energy, the world's largest heterojunction (HJT) product manufacturer, has unveiled its latest innovation in high-efficiency modules, featuring groundbreaking zero busbar (0BB) technology. This cutting-edge advancement has been seamlessly...